Press Releases
GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey
GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
GT Biopharma to Present at Upcoming September Investor Conferences
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer
GT Biopharma Provides Second Quarter 2021 Business Update
